Abstract:Chemotherapy has become an emerging strategy to activate cytotoxic T cell responses by inducing immunogenic cell death (ICD), but the level of antitumor immunity induced by chemotherapeutic agents, such as oxaliplatin (OXA), is limited due to inadequate tumor antigen presentation and T cell activation. Inducing autophagic cell death (ACD) promotes the release of tumor antigen and the recruitment of dendritic cells, therefore strengthening antitumor immune responses. Here we simultaneously activate ICD and ACD with tumor targeting micelle to achieve enhanced antitumor chemo-immunotherapy. A self-delivery micelle is formulated by conjugating OXA prodrug with tocopherol succinate (TOS) as a hydrophobic segment and further encapsulates autophagy activator SMER28 to afford TOPR/SMER28, which specifically targets αvβ3 on tumor cells with c(RGDfK). Upon cellular internalization, OXA is released from the prodrug in response to the high concentration of reduced glutathione (GSH) in tumor cells, triggering ICD and releasing associated molecular patterns (DAMPs) signaling molecules to stimulate immunity. Meanwhile, SMER28 over-activates autophagy to induce autophagic cell death, which further leads to the maturation of dendritic cells and ultimately activates anti-tumor immune response. In the 4T1 tumor-bearing mice, the combination of OXA and SMER28 effectively inhibits tumor growth and activates antitumor immune responses. The tumor targeted micelle releases OXA and SMER28 in an on-demand profile and strengthens tumor chemo-immunotherapy by synergizing ICD and ACD, providing an alternative for antitumor immunotherapy. STATEMENT OF SIGNIFICANCE: Chemotherapy induces immunogenic cell death (ICD) to activate anti-tumor immunity. However, the efficacy is limited by low levels of antigen presentation and T cell activation. To strengthen the antitumor immune responses induced by ICD, we first combine autophagic cell death (ACD) with ICD by formulating a glutathione-responsive oxaliplatin prodrug micelle co-encapsulating the autophagy activator SMER28. The activated autophagic level by SMER28 enhances the release of antigen and the recruitment of APCs, and ultimately bolsters T cell-mediated antitumor immune responses. We provide a potential strategy to amplify antitumor immune effects by combining autophagy activation with chemotherapy.

Combining Immune Checkpoint Blockade with ATP-based Immunogenic Cell Death Amplifier for Cancer Chemo-Immunotherapy.

Tumor-permeated ATP-based size-controllable immunogenic cell death amplifier remodel immunosuppressive microenvironment to boost cancer immunotherapy

Interference of ATP‐Adenosine Axis by Engineered Biohybrid for Amplifying Immunogenic Cell Death‐Mediated Antitumor Immunotherapy

ATP-adenosine axis regulation combined with microneedle assisted photoimmunotherapy to boost the immunotherapy efficiency

Synergistic Reinforcing of Immunogenic Cell Death and Transforming Tumor‐Associated Macrophages Via a Multifunctional Cascade Bioreactor for Optimizing Cancer Immunotherapy

A Cascade-Targeted Enzyme-Instructed Peptide Self-Assembly Strategy for Cancer Immunotherapy through Boosting Immunogenic Cell Death

Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy

Enzyme-instructed and mitochondria-targeting peptide self-assembly to efficiently induce immunogenic cell death

Reinforcing the Induction of Immunogenic Cell Death Via Artificial Engineered Cascade Bioreactor‐Enhanced Chemo‐Immunotherapy for Optimizing Cancer Immunotherapy

Tumor Cell Surface Modification with Immuno-Amplified Nanoparticles to Enhance Cancer Immunotherapy

Self-Assembled Immunostimulatory Tetrahedral Framework Nucleic Acid Vehicles for Tumor Chemo-immunotherapy

Synergizing autophagic cell death and oxaliplatin-induced immunogenic death by a self-delivery micelle for enhanced tumor immunotherapy

Improving combination cancer immunotherapy by manipulating dual immunomodulatory signals with enzyme-triggered, cell-penetrating peptide-mediated biomodulators

Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme

Self-sacrificed construction of versatile nanoadjuvant for synergistically enhanced immunogenic cell death and improved anti-tumor immunity

Stimuli-responsive Nano Vehicle Enhances Cancer Immunotherapy by Coordinating Mitochondria-Targeted Immunogenic Cell Death and PD-L1 Blockade

A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade

Ferroptosis Amplifier Remodels Redox Homeostasis for Enhanced Cancer Chemoimmunotherapy

Combination of Oxaliplatin and POM-1 by Nanoliposomes to Reprogram the Tumor Immune Microenvironment

A Self-Cascade Terpolymer Platform for Amplified Chemo-Chemodynamic Therapy with Synergistic Immunogenic Cell Death Enhancement

Massively Evoking Immunogenic Cell Death by Focused Mitochondrial Oxidative Stress Using an AIE Luminogen with a Twisted Molecular Structure.